Waters KD - Search Results

1

Advances in childhood leukaemia: successful clinical-trials research leads to individualised therapy.

Ziegler DS, Dalla Pozza L, Waters KD, Marshall GM. Ziegler DS, et al. Among authors: waters kd. Med J Aust. 2005 Jan 17;182(2):78-81. doi: 10.5694/j.1326-5377.2005.tb06581.x. Med J Aust. 2005. PMID: 15651967 Review.

2

Importance of minimal residual disease testing during the second year of therapy for children with acute lymphoblastic leukemia.

Marshall GM, Haber M, Kwan E, Zhu L, Ferrara D, Xue C, Brisco MJ, Sykes PJ, Morley A, Webster B, Dalla Pozza L, Waters K, Norris MD. Marshall GM, et al. J Clin Oncol. 2003 Feb 15;21(4):704-9. doi: 10.1200/JCO.2003.10.080. J Clin Oncol. 2003. PMID: 12586809

3

Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia.

Sutton R, Venn NC, Tolisano J, Bahar AY, Giles JE, Ashton LJ, Teague L, Rigutto G, Waters K, Marshall GM, Haber M, Norris MD; Australian and New Zealand Children's Oncology Group. Sutton R, et al. Br J Haematol. 2009 Aug;146(3):292-9. doi: 10.1111/j.1365-2141.2009.07744.x. Epub 2009 Jun 3. Br J Haematol. 2009. PMID: 19500099 Free article. Clinical Trial.

4

Characterization of clonal immunoglobulin heavy chain and I cell receptor gamma gene rearrangements during progression of childhood acute lymphoblastic leukemia.

Marshall GM, Kwan E, Haber M, Brisco MJ, Sykes PJ, Morley AA, Toogood I, Waters K, Tauro G, Ekert H, et al. Marshall GM, et al. Leukemia. 1995 Nov;9(11):1847-50. Leukemia. 1995. PMID: 7475273

5

Determining the repertoire of IGH gene rearrangements to develop molecular markers for minimal residual disease in B-lineage acute lymphoblastic leukemia.

Brisco MJ, Latham S, Sutton R, Hughes E, Wilczek V, van Zanten K, Budgen B, Bahar AY, Malec M, Sykes PJ, Kuss BJ, Waters K, Venn NC, Giles JE, Haber M, Norris MD, Marshall GM, Morley AA. Brisco MJ, et al. J Mol Diagn. 2009 May;11(3):194-200. doi: 10.2353/jmoldx.2009.080047. Epub 2009 Mar 26. J Mol Diagn. 2009. PMID: 19324994 Free PMC article.

6

A pilot study of EVAP/ABV chemotherapy in 25 newly diagnosed children with Hodgkin's disease.

Ekert H, Fok T, Dalla-Pozza L, Waters K, Smith P, White L. Ekert H, et al. Br J Cancer. 1993 Jan;67(1):159-62. doi: 10.1038/bjc.1993.28. Br J Cancer. 1993. PMID: 7678978 Free PMC article. Clinical Trial.

7

Results of cessation of treatment in childhood acute lymphocytic leukaemia.

Ekert H, Balderas A, Waters KD, Matthews RN. Ekert H, et al. Among authors: waters kd. Med J Aust. 1981 May 16;1(10):523-5. doi: 10.5694/j.1326-5377.1981.tb135780.x. Med J Aust. 1981. PMID: 6942206

8

Poor outlook for childhood acute lymphoblastic leukaemia with relapse.

Ekert H, Ellis WM, Waters KD, Matthews RN. Ekert H, et al. Among authors: waters kd. Med J Aust. 1979 Sep 8;2(5):224-6. doi: 10.5694/j.1326-5377.1979.tb127098.x. Med J Aust. 1979. PMID: 292827

9

Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction.

Brisco MJ, Condon J, Hughes E, Neoh SH, Sykes PJ, Seshadri R, Toogood I, Waters K, Tauro G, Ekert H, et al. Brisco MJ, et al. Lancet. 1994 Jan 22;343(8891):196-200. doi: 10.1016/s0140-6736(94)90988-1. Lancet. 1994. PMID: 7904666

10

Aspergillus laryngotracheobronchial infection in a 6-year-old girl following bone marrow transplantation.

Barnes C, Berkowitz R, Curtis N, Waters K. Barnes C, et al. Int J Pediatr Otorhinolaryngol. 2001 May 31;59(1):59-62. doi: 10.1016/s0165-5876(01)00429-3. Int J Pediatr Otorhinolaryngol. 2001. PMID: 11376819

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

73 results

Search Page

Filters